Press releases
- FDA approves Nucala (mepolizumab) 40 mg prefilled syringe for children with severe eosinophilic asthma
- Routine Vaccination Rates in Teens and Adults Continue to Lag Behind Pre-Pandemic Levels, Follow-up Analysis Shows
- Tony Wood appointed Chief Scientific Officer designate, GSK
Tweets from GSK US
-
GSKUS @GSKUS
Severe asthma can have an impact on a patient’s quality of life, as their asthma symptoms can remain uncontrolled despite high-dose standard treatments. Learn more about our new administration option: gsk.to/3H555R8
about 1 day ago
-
GSKUS @GSKUS
A follow-up claims analysis commissioned by GSK & conducted by @avalerehealth showed routine vaccination rates for teens & adults continue to lag behind pre-pandemic levels. It's important we raise awareness of routine vaccines for public safety. Details: gsk.to/32rHV8g
about 2 days ago
-
GSKUS @GSKUS
#BreakingNews: the @US_FDA approved our new treatment administration option. Click below to learn more: gsk.to/3tV0Dkb
about 2 days ago
